TY - JOUR
T1 - Biomarkers for early detection of colorectal cancer
T2 - The early detection research network, a framework for clinical translation
AU - Bresalier, Robert S.
AU - Grady, William M.
AU - Markowitz, Sanford D.
AU - Nielsen, Hans Jørgen
AU - Batra, Surinder K.
AU - Lampe, Paul D.
N1 - Funding Information:
W.M. Grady is an advisory board member for Freenome and SEngine, is a consultant for Guardant Health and DiaCarta, and reports receiving a commercial research grant from Janssen. S.D. Markowitz is a board member and consultant for Lucid Diagnostics, reports receiving a commercial research grant from Lucid Diagnostics, and has ownership interest (including patents) in Lucid Diagnostics and Exact Sciences. P.D. Lampe has ownership interest in a patent. No potential conflicts of interest were disclosed by the other authors.
Funding Information:
All authors are members and investigators of the NCI's Early Detection Research Network (EDRN). R.S. Bresalier's work was supported by NIH NCI grant UO1 CA86400, the State of Texas Cancer Prevention Research Institute (CPRIT DP150059), The University of Texas MD Anderson's Colorectal Cancer Moonshot Program, an endowment from the Birdie J and Lydia J Resoft Distinguished Professorship in Gastrointestinal Oncology, and a charitable distribution from W. Steve and Luanne Bozeman. P.D. Lampe's work was supported by NIH NCI grant U01CA152637. S.D. Markowitz's work was supported by PHS CA152756.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/12
Y1 - 2020/12
N2 - Early detection by screening significantly reduces mortality from colorectal cancer, but 40% of guideline-eligible patients are not screened as recommended in the United States. Novel strategies to improve screening uptake overall and efforts to deploy best practices to underserved populations are a high priority for health care. This review focuses on existing biomarkers in practice and those in development with clinical relevance to early detection of colorectal neoplasia, with an emphasis on those developed by investigators of the NCI's Early Detection Research Network. Aberrantly methylated DNA markers (blood and stool), stool-based markers (including fecal immunochemical test-DNA), and a variety of blood-based marker assays in development (protein markers, glycoproteins including mucins, and cell-free DNA tests) are reviewed. Individual markers and biomarker panels, sample resources, and barriers to translating biomarkers to clinical practice are discussed.
AB - Early detection by screening significantly reduces mortality from colorectal cancer, but 40% of guideline-eligible patients are not screened as recommended in the United States. Novel strategies to improve screening uptake overall and efforts to deploy best practices to underserved populations are a high priority for health care. This review focuses on existing biomarkers in practice and those in development with clinical relevance to early detection of colorectal neoplasia, with an emphasis on those developed by investigators of the NCI's Early Detection Research Network. Aberrantly methylated DNA markers (blood and stool), stool-based markers (including fecal immunochemical test-DNA), and a variety of blood-based marker assays in development (protein markers, glycoproteins including mucins, and cell-free DNA tests) are reviewed. Individual markers and biomarker panels, sample resources, and barriers to translating biomarkers to clinical practice are discussed.
UR - http://www.scopus.com/inward/record.url?scp=85099982396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099982396&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-20-0234
DO - 10.1158/1055-9965.EPI-20-0234
M3 - Review article
C2 - 32299850
AN - SCOPUS:85099982396
SN - 1055-9965
VL - 29
SP - 2431
EP - 2440
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 12
ER -